ArticleJournal of neurology2026
Profiles of patients at early stages of Huntington's disease based on the routine biological markers and the disease progression.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHuntington's disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. Many studies attempt, besides age and CAG, to understand the factors that impact disease progression. Biological tests measuring several metabolic and inflammatory factors are frequently performed in outpatients, but their relation with disease progression is unknown. This study aims to evaluate the association between routine biological profiles at the early manifest stage of HD and subsequent disease progression.
methodsFrom 2936 participants, the SPOT-HD database (combination of French part of REGISTRY, BIO-HD and REPAIR-HD), we selected 227 HD mutation carriers at an early stage of HD (HD-ISS stage 2 and CAP < 150), having both longitudinal measurements of routine blood biomarkers and clinical progression assessed using the Unified Huntington's Disease Rating Scale. Identification of biological routine profiles was performed using an iterative non-parametric model selection with dimensionality reduction algorithm, k-means clustering, LASSO regression, and Random Forest. Disease progression of each profile was estimated using generalized additive modeling.
resultsThree profiles were identified with distinct trajectories of HD progression (p < 0.001). The Rapid-Progression Profile with relatively higher levels of triglycerides, liver enzymes, and body mass index, coupled with lower high-density lipoprotein (HDL) cholesterol levels was noted. The Intermediate-Progression profile with relatively higher HDL levels, lower triglycerides, and inflammatory and liver markers in the lower end of the normal range was noticed. The Slow-Progression Profile with a tendency for higher T4 and creatinine levels, a greater concentration of lymphocytes than in other profiles, and low HDL despite normal triglycerides were studied.
conclusionBiological routine profiles may help anticipating HD progression, thus facilitating personalized medicine approaches. These findings suggest that routine metabolic and inflammatory markers may be useful for patient follow-up in HD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.